KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors.
As with many malignancies, cytogenetic information has become increasingly important to the diagnosis and proper treatment of colorectal cancer. In particular, several recent studies have confirmed that KRAS is not only one of the most commonly mutated genes in colorectal cancer, but also essential to treatment decision-making. Several key studies have demonstrated that patients with mutant KRAS do not respond to treatment with epidermal growth factor inhibitors. This finding has several implications for clinicians who treat patients with metastatic colorectal cancer. The following monograph includes discussions on the key issues surrounding the integration of recent data on KRAS status into the care of patients with this disease.
Lenz
Heinz-Josef
HJ
Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Chu
Edward
E
Grothey
Axel
A
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D000068818:Cetuximab; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary / Q000628:therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D009154:Mutation; D000077544:Panitumumab; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins / Q000235:genetics*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D000077544:Panitumumab; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins; D000068818:Cetuximab